CHMP1B2P: A Drug Target / Disease Biomarker (G101060146)

Target Name: CHMP1B2P

NCBI ID: G101060146

CHMP1B2P

Other Name(s): charged multivesicular body protein 1B2, pseudogene | Charged multivesicular body protein 1B2, pseudogene

CHMP1B2P: A Drug Target / Disease Biomarker

CHMP1B2P is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is cytoskeleton-associated protein 1B (CHMP1B2P), and it is a member of the cytoskeleton-associated protein family 1 (CAPN) gene.

CHMP1B2P is known for its role in the development and maintenance of the cytoskeleton, which is the protein structure that makes up the cytoplasm of cells. The cytoskeleton provides structural support, helps maintain cell shape, and plays a role in cell division and transport of organelles within the cell.

CHMP1B2P is also involved in a variety of cellular processes that are important for maintaining cellular homeostasis. For example, it helps regulate the movement of cells along the direction of the force of gravity, which is important for the proper functioning of cells and the development of tissues.

In addition to its role in cytoskeleton development and maintenance, CHMP1B2P is also involved in the regulation of cellular processes that are important for the survival and growth of cells. For example, it has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death.

CHMP1B2P is also a potential drug target for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its expression has been shown to be elevated in a variety of tissues and has been linked to the development and progression of certain diseases.

One of the key challenges in studying CHMP1B2P is its relatively high level of expression, which can make it difficult to study in detail. Additionally, the functions of CHMP1B2P are not well fully understood, which can make it difficult to predict the effects of potential drug targets.

Despite these challenges, research into CHMP1B2P is ongoing, and several studies have identified potential drug targets for this protein. One of the most promising targets for CHMP1B2P is the protein p16INK4a, which is a known regulator of the T-cell receptor signaling pathway.

Research has shown that p16INK4a can interact with CHMP1B2P and that the expression of p16INK4a is influenced by the expression of CHMP1B2P. Additionally, several studies have shown that inhibiting the activity of p16INK4a has the potential to therapeutic effects in a variety of diseases, including cancer and neurodegenerative diseases.

Another potential drug target for CHMP1B2P is the protein p53, which is a well-known regulator of the DNA damage response. Several studies have shown that CHMP1B2P can interact with p53 and that the expression of p53 is influenced by the expression of CHMP1B2P.

Additionally, CHMP1B2P has also been shown to interact with several other proteins, including the protein FBN1, which is involved in the regulation of blood clotting; and the protein CSN2, which is involved in the regulation of cell adhesion.

In conclusion, CHMP1B2P is a protein that is involved in a variety of cellular processes that are important for the development and maintenance of tissues. Its role in cytoskeleton development and maintenance, as well as its potential involvement in the regulation of cellular processes that are important for the survival and growth of cells, make it an attractive target for drug research.

The study of CHMP1B2P is ongoing, and several studies have identified potential drug targets for this protein. Further research is needed to fully understand the functions of CHMP1B2P and its potential as a drug target.

Protein Name: Charged Multivesicular Body Protein 1B2, Pseudogene

The "CHMP1B2P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHMP1B2P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets